Cell & gene therapy supply chains are inherently complex, requiring the utmost attention to quality, cold chain logistics, and chain of custody requirements. As these novel therapeutics demonstrate efficacy and feasibility of implementation in health systems worldwide, innovators are expanding their targets to include new therapeutic areas, and more and more often acute indications. These indications require a new, more dynamic distribution model to ensure that drug reaches patient at the right time, with the same requirement of flawless execution in order to maintain quality standards. Join Thermo Fisher Scientific and Pluristem Therapeutics as we discuss lessons learned in developing the just-in-time supply chain for their phase III hip fracture study, and how these lessons are being used in their current efforts to treat severe COVID-19 cases complicated by Acute Respiratory Distress Syndrome (ARDS) in the United States.

Featured Speakers

Caitlin Cumming

Director, Cell & Gene Therapy, Fisher Clinical Services
Thermo Fisher Scientific

Caitlin Cumming is the Director of Cell & Gene Therapy for Bioservices & Specialty Logistics in Thermo Fisher Scientific. Caitlin leads strategic planning and service line enhancement for cell & gene therapy customers, focusing on ultracold and cryogenic cold chain services, including GMP storage, packaging, labeling, and global distribution for clinical trials. Caitlin has been with Thermo Fisher for five years in a variety of marketing and commercial roles, and has an MBA/MPH from Boston University. 

Lior Raviv

VP Development & Operations
Pluristem Therapeutics

Lior Raviv joined Pluristem in 2011 and currently serves as vice president of Development & Operations in charge on process and Technology development, Manufacturing and Operations. Prior to that, Lior served as process development engineer, projects manager and product development team leader at Pluristem in charge of new technologies and process development. Prior to joining Pluristem, Lior spent 2010-11 in the position of R&D analytical researcher at Teva Pharmaceutical Industries. He holds a master’s in pharmacology from Ben-Gurion University and a bachelor’s in biotechnology engineering from Ben-Gurion University.

Date:  Tuesday, July 21, 2020
Time:  10am ET / 7am PT
Duration:  1 Hour

Register now for this webinar